Combination of atomoxetine with the novel antimuscarinic aroxybutynin improves mild to moderate OSA

医学 羟丁酸 安慰剂 阿托莫西汀 四分位间距 麻醉 不利影响 随机对照试验 临床终点 呼吸暂停 睡眠呼吸暂停 多导睡眠图 呼吸不足 阻塞性睡眠呼吸暂停 内科学 膀胱过度活动 注意缺陷多动障碍 替代医学 哌醋甲酯 病理 精神科
作者
Russell Rosenberg,Brian Abaluck,Stephen Thein
出处
期刊:Journal of Clinical Sleep Medicine [American Academy of Sleep Medicine]
卷期号:18 (12): 2837-2844 被引量:7
标识
DOI:10.5664/jcsm.10250
摘要

Obstructive sleep apnea is a common and serious sleep disorder for which treatment remains challenging due to lack of adherence to approved therapies. Previous pharmacological studies addressing sleep-related upper airway muscle hypotonia suggested that the combination of atomoxetine and oxybutynin is effective in treating obstructive sleep apnea. The current study is with aroxybutynin (AD109), a new enantiomerically pure form of oxybutynin with better safety profile compared to racemic oxybutynin.This was a randomized, double-blind, placebo-controlled, crossover study in patients with mild to moderate obstructive sleep apnea. Each received low-dose AD109 (37.5/2.5 mg), high-dose AD109 (75/2.5 mg), and placebo at bedtime across 3 overnight periods in a randomized order. Adverse events were collected by telephone contact with participants during each washout period. The primary endpoint was change in hypoxic burden and secondary endpoint was apnea-hypopnea index.Patients treated with both the high and low doses of AD109 had a statistically significant and clinically meaningful difference from placebo in hypoxic burden. Median [interquartile range] hypoxic burden for participants on placebo was 13.9[4.5-21.9] (%min)/h vs 2.3[0.1-10.5] (%min)/h for patients on the high dose (P < .001) and to 7.3[2-12.5] (%min)/h on the low dose (P < .01). Apnea-hypopnea index went from a median of 13.2[8.0-19.1] events/h on placebo reduced to 5.5[2.2 to 9.6] events/h on the high dose (P < .001) and to 7.8[4-13.7] events/h on the low dose (P < .05). AD109 demonstrated a favorable safety profile.This study provides additional support that a pharmacological intervention for obstructive sleep apnea, namely the combination of atomoxetine and aroxybutynin, offers promising results. Additional development of this compound and others is warranted.Registry: ClinicalTrials.gov; Name: AD109 Dose Finding in Mild to Moderate OSA; URL: https://clinicaltrials.gov/ct2/show/NCT04631107; Identifier: NCT04631107.Rosenberg R, Abaluck B, Thein S. Combination of atomoxetine with the novel antimuscarinic aroxybutynin improves mild to moderate OSA. J Clin Sleep Med. 2022;18(12):2837-2844.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
善良书南完成签到,获得积分20
刚刚
小白猫发布了新的文献求助10
1秒前
1秒前
benben发布了新的文献求助10
1秒前
飘逸夜南完成签到,获得积分10
1秒前
入司的应助被cccfeng1231采纳,获得10
1秒前
1秒前
2秒前
momo完成签到,获得积分10
2秒前
2秒前
Yes发布了新的文献求助10
2秒前
DDZ发布了新的文献求助10
4秒前
噜噜噜的应助被蒸点粥七七采纳,获得10
4秒前
秋风的应助被蒸点粥七七采纳,获得10
4秒前
4秒前
尘骉完成签到,获得积分10
4秒前
4秒前
4秒前
CarryLJR发布了新的文献求助30
5秒前
OLDcorn发布了新的文献求助10
5秒前
6秒前
Arain456完成签到 ,获得积分10
6秒前
hodme1完成签到,获得积分10
6秒前
暗觉发布了新的文献求助10
7秒前
march发布了新的文献求助10
10秒前
keyan完成签到 ,获得积分10
11秒前
伶俐云朵完成签到,获得积分10
11秒前
jyxm完成签到,获得积分10
12秒前
呆瓜不呆的应助被温暖砖头采纳,获得10
12秒前
可乐爱喝奶茶完成签到,获得积分10
12秒前
13秒前
14秒前
成就念芹发布了新的文献求助10
14秒前
请输入昵称完成签到 ,获得积分10
15秒前
lili发布了新的文献求助10
16秒前
17秒前
无情醉易发布了新的文献求助10
17秒前
18秒前
18秒前
曦_完成签到,获得积分10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175534
求助须知:如何正确求助?哪些是违规求助? 9567220
关于积分的说明 21791292
捐赠科研通 7770111
什么是DOI,文献DOI怎么找? 3431868
关于科研通互助平台的介绍 2556244
邀请新用户注册赠送积分活动 2477299